Stripe and AI Leaders Anthropic, OpenAI Pledge $500M to Wipe Out Respiratory Viruses

A $500 Million Shot at the Common Cold

Stripe, the payments giant founded by brothers Patrick and John Collison, is spearheading a new $500 million nonprofit called Intercept with the ambitious goal of preventing—and eventually eliminating—respiratory infections like the common cold and influenza. The effort has attracted backing from prominent AI companies Anthropic and OpenAI, along with Bill Gates, the Flu Lab, and traders from the quantitative fund Jane Street Capital. The funding will be used to develop broad-spectrum vaccines, antiviral nasal sprays, and large-scale air-cleaning systems, deploying modern technologies that have so far bypassed the sniffles.

Why the Common Cold Has Defied Science

On average, people spend 5% of their lives battling colds or the flu, according to Stripe executive Nan Ransohoff, who is leading Intercept alongside venture capitalist Charlie Petty. Yet drug companies rarely pursue prevention. The core challenge is virological: more than 200 different viruses cause cold-like symptoms, with rhinoviruses being the most frequent. A vaccine targeting just one or two strains would have marginal public-health impact, making the business case unsalable. “When pharma companies look at it, it’s not as attractive as other things they could work on,” Ransohoff said. “So it hasn’t attracted the resources.” Intercept’s founding premise is that this is an incentive failure, not a technical dead end. The nonprofit model, modeled after Stripe’s $1.8 billion carbon-removal market-commitment program Frontier, aims to bridge that gap by directly funding high-risk, high-reward research.

AI and Protein Design Enter the Fight

The initiative draws on computational advances heavily backed by the AI community. David Veesler, a structural biologist at the University of Washington who convinced Ransohoff of the feasibility, points to a growing kit of tools: RNA-based drugs, monoclonal antibodies, and computational protein design. One idea is to create engineered proteins that could be sprayed in the nasal passages, acting as molecular traps that catch incoming viruses before they can infect cells. Veesler noted that researchers can now design such proteins with atomic-level precision using software tools that emerged from the DeepMind-led protein-structure revolution—technology that is also at the core of many Anthropic and OpenAI safety-adjacent initiatives. “The more we thought about it, the more we realized that many of these problems have not been worked on with modern technologies,” Veesler said. The involvement of Anthropic and OpenAI as funders, rather than research partners, underscores how the AI industry is increasingly financing biology moonshots that require computing power and algorithmic insight.

Advisory Muscle from Pandemic Veterans

Intercept’s advisory board includes two figures who shaped the US response to covid-19: Peter Marks, a former top official at the Food and Drug Administration, and Moncef Slaoui, the pharmaceutical executive who led Operation Warp Speed. Their involvement signals that the project will pursue regulatory and development pathways proven during the pandemic, when vaccines and antivirals were delivered in record time. Ransohoff likened the effort to the covid response, where a coalition of public and private actors overcame decades of inertia. The nonprofit will fund grants and equity investments across multiple approaches simultaneously—engineered antibodies, broad-spectrum vaccines, and hardware like germicidal UV or HEPA-based air-cleaning installations—to create a defense-in-depth against transmission.

The Broader Context: Scaling Prevention in a Warming World

While Intercept’s focus is biomedical and mechanical prevention, its timing is notable. Europe is currently grappling with a record-breaking heat wave that is straining power grids and highlighting how climate change amplifies public-health infrastructure challenges. Although the heat wave is not directly related, both stories converge on the recognition that existing systems are brittle. Ransohoff said the goal is to treat respiratory infections as a societal burden that has been “really underweighted,” an argument that resonates in the wake of a pandemic. Early work will include pilot installations of air-cleaning systems in schools and offices, which could be rapidly scaled if field studies prove efficacy. The $500 million fund is structured to last several years and will prioritize projects that can show a path to self-sufficiency, much as Frontier’s advance market commitments have pulled carbon-removal startups toward commercialization.

What to Watch Next

Intercept’s success will depend on whether it can catalyze the development of truly broad-spectrum interventions—a scientific challenge that has evaded major pharma. If Veesler’s lab and other grantees can demonstrate a nasal spray or vaccine candidate that works against a wide family of rhinoviruses, the nonprofit could attract follow-on funding from governments and private investors, potentially reshaping the $40 billion respiratory drug market. The backing of Anthropic and OpenAI also hints at a future where AI-designed proteins move from in silico predictions to real-world products. For now, the initiative is a notable test case: can the forward-deployed capital of the tech world solve a problem that has been hiding in plain sight? The answer, researchers say, may arrive faster than a common cold.